All News

Fear of cancer recurrence is a common issues survivors face. The struggle is real to keep it in its proper place. Read how one survivor sees the struggle.

Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.

While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.

The FDA has accepted a supplemental biologics license application (sBLA) for the use of Keytruda (pembrolizumab) as an adjuvant treatment for patients with resected, high-risk stage 3 melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.

The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

An IBC patient reflects on her search for an alternative to conventional treatment.

There can be definite struggles for childhood cancer survivors, even many years later.

A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.

Stand Up To Cancer’s “interception” trials tackle lung and pancreatic disease early, with the goal of preventing progression to advanced stages.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

What to do when cancer isn't ruining your summer...

A new book delves into the stories of 25 immunotherapy pioneers and the history of the field they helped to develop.

Part three in a three part series about my trip to Chicago for HealtheVoices 2018.

This year’s survey is expanded to better learn about the experience of caregivers, with a selection of questions specifically for them. The Alliance asks that just one caregiver per patient fill out the survey.

Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.

The American Society of Clinical Oncology issued guidelines in 2017 to support the use of meditation, yoga, acupuncture and music therapy among to help relieve side effects from cancer treatment.

CURE spoke with the chief medical officer of the Leukemia & Lymphoma Society to hear what she thinks are important next steps in improving patient outcomes.

An MPN diagnosis can be overwhelming, but here are some of the basic facts every newly diagnosed patient should know.

Immunotherapy’s effectiveness may depend on the bacteria living in patients’ gastrointestinal tracts, studies show.

Novel immunotherapies either release the immune system’s parking brake or hit its gas pedal.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

Sometimes the people who inspire us are closer than we realize.

The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds

Treatment with chimeric antigen receptor (CAR)-T cell therapy showed encouraging rates of durable responses among adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the pivotal JULIET trial.

A cancer diagnosis means lots of treatment appointments, decisions to make and fears to face. Setting goals, whether short-term or long-term, can help get you through the journey.

Part two in a three-part series about my trip to Chicago for HealtheVoices 2018.